Understanding EP-NEC: Through Diagnosis, Treatment, and Support

Understanding EP-NEC: Through Diagnosis, Treatment, and Support

In this podcast, Medical Oncologist, Dr Aman Chauhan and Neuroendocrine Patient Advocate, Susan Meckler-Plummer, discuss extrapulmonary high-grade neuroendocrine carcinomas (EP-NECs), a rare, aggressive, and often misunderstood subset of neuroendocrine cancers.

They clarify the crucial differences between NETs and NECs, explain why accurate classification and rapid treatment are essential, and highlight current and emerging therapeutic approaches, including DLL3-targeted therapies.

Through both HCP and patient-centred perspectives, the conversation addresses real-world challenges, the importance of support networks, and the growing sense of hope for people affected by this difficult disease.

Key clinical takeaways:

  • Unlike NETs, EP-NECs are poorly differentiated, high-grade, aggressive, and fast-growing cancers, with a need for more effective treatments
  • While there remains a medical need for effective treatment of EP-NECs, clinical studies with DLL3-targeted agents show promise
  • Accessing a support network can provide emotional reinforcement and information for patients and their care partners

You can also watch a video of the experts in conversation and download the accompanying transcript on our website: https://cor2ed.com/net-connect/programmes/ep-nec-diagnosis-treatment-support/?media=0

Or watch on YouTube: https://youtu.be/nfng2s3jSw8

Follow us on social media:

LinkedIn: https://www.linkedin.com/company/cor2ed-net-connect/?viewAsMember=true

X:https://x.com/net_connectinfo

This podcast is supported by an Independent Education Grant from Boehringer Ingelheim.

This podcast is developed by cor2ed.com

Published in November 2025

Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.

Episoder(92)

Pre-analytical phase challenges and biomarker testing in HER2+ metastatic breast cancer

Pre-analytical phase challenges and biomarker testing in HER2+ metastatic breast cancer

Pre-analytical Phase Challenges and Biomarker Testing in HER2+ Metastatic Breast Cancer    Key clinical takeaways:   Metastatic breast cancer (mBC) is a complex, heterogeneous disease requiring multi...

12 Mar 23min

Metastatic breast cancer: Understanding HER2-low and HER2-ultralow classification

Metastatic breast cancer: Understanding HER2-low and HER2-ultralow classification

Understanding HER2-low and HER2-ultralow classification in mBC In this video podcast moderated by the Oncology Brothers, Dr Komal Jhaveri provides a practical overview of how this shift beyond a binar...

17 Des 202525min

Exploring the role of targeted radiopharmaceutical treatment in NETs

Exploring the role of targeted radiopharmaceutical treatment in NETs

How are advances in radioligand therapy shaping the treatment of neuroendocrine tumours, and what does recent trial evidence tell us? What are the key considerations for patient selection, sequencing,...

30 Sep 202521min

Tackling mPDAC: chemotherapy strategies that matter

Tackling mPDAC: chemotherapy strategies that matter

Metastatic pancreatic ductal adenocarcinoma (mPDAC) is notoriously aggressive with a poor prognosis. It is often diagnosed late, and by this time, surgery is usually not an option. Median overall surv...

19 Mai 202521min

Understanding Rare NSCLC Mutations: Insights, access and support

Understanding Rare NSCLC Mutations: Insights, access and support

Listen to a revealing conversation between Dr Joshua Sabari, a Medical Oncologist specialising in the treatment of rare alternations of NSCLC and Debra Montague, President of Lung Cancer Europe (LuCE)...

14 Mai 202520min

The HER2 diagnostic and treatment landscape in NSCLC

The HER2 diagnostic and treatment landscape in NSCLC

Episode 2: Navigating common treatment scenarios in HER2-mutant NSCLC  This is the second episode of a two-part series on the HER2 diagnostic and treatment landscape in NSCLC, hosted by the Oncology B...

28 Apr 202518min

The HER2 Diagnostic and Treatment Landscape in NSCLC

The HER2 Diagnostic and Treatment Landscape in NSCLC

Episode 1: Identifying HER2-directed NSCLC: The Medical Oncologist and Pathologist perspectives  This is the first episode of a two-part series on the HER2 diagnostic and treatment landscape in NSCLC,...

15 Apr 202521min

Populært innen Fakta

fastlegen
dine-penger-pengeradet
relasjonspodden-med-dora-thorhallsdottir-kjersti-idem
rss-strid-de-norske-borgerkrigene
mikkels-paskenotter
foreldreradet
rss-bisarr-historie
treningspodden
jakt-og-fiskepodden
sinnsyn
rss-kunsten-a-leve
hverdagspsyken
ukast
rss-sunn-okonomi
rss-bak-luftfarten
fryktlos
tomprat-med-gunnar-tjomlid
lederskap-nhhs-podkast-om-ledelse
gravid-uke-for-uke
hagespiren-podcast